Ozempic (semaglutide) is a GLP-1 receptor agonist administered subcutaneously for type 2 diabetes management Lumps commonly form due to injection technique errors including inadequate site rotation, injecting too rapidly, or removing the needle too soon after injection Normal lumps are firm, mobile, mildly tender, and gradually reduce in size without warmth, spreading redness, or systemic symptoms Seek medical attention for progressive enlargement, increasing pain, signs of infection (warmth, discharge, fever), or difficulty breathing Prevention requires proper technique including systematic site rotation (23 cm from previous sites), keeping the needle in place for at least 6 seconds post-injection, and never reusing needles Lipohypertrophy (persistent rubbery lumps from repeated injections in the same area) impairs medication absorption and requires strict site avoidance Table of Contents Why Lumps Form After Ozempic Injections Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist administered subcutaneously for the management of type 2 diabetes mellitus
Studies have found that using terms like nanoencapsulation can trigger more concern than terms like emulsion or colloid, even if scientifically they refer to similar structures
Compounded medications are not the same as commercially available FDA-approved branded medications
Nausea typically emerges first, often appearing within 24 hours as your body adjusts to the medication's mechanism
The daily requirement is the most commonly cited drawback
Some people experience both symptoms at different points in their treatment
